23 May 2013
Keywords: BioCryst, Presidio, M&A, Antivirals, Hepatitis C
Article | 22 October 2012
USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately held Presidio Pharmaceuticals in an all-stock ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 October 2012
21 October 2012
23 October 2012
© 2013 thepharmaletter.com